Other Clinical Trial - A Study to Examine the Effect of Reconval K1 Cream

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic colorectal cancer patients. This study will prospectively accrue metastatic colorectal patients receiving EGFRI and treat with reconval cream half face versus placebo cream half face to study whether Vitamin k1 cream can prevent the typical skin eruption caused by EGFRI.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02239731` - Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients	Phase 2

NCT number	NCT01763307
Study type	Interventional
Source	Hadassah Medical Organization
Contact
Status	Completed
Phase	Phase 2
Start date	January 2013
Completion date	December 2018

A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI — EGFRI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms